Which has preferable earnings and valuation, BSX or STE?

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boston Scientific $20.07B 3.46 $2.90B $2.39 19.53 STERIS $5.94B 3.38 $782.30M $7.93 25.95

Does the media refer more to BSX or STE?

In the previous week, Boston Scientific had 40 more articles in the media than STERIS. MarketBeat recorded 58 mentions for Boston Scientific and 18 mentions for STERIS. Boston Scientific's average media sentiment score of 1.31 beat STERIS's score of 0.98 indicating that Boston Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 51 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive STERIS 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STE or EW?

In the previous week, STERIS had 4 more articles in the media than Edwards Lifesciences. MarketBeat recorded 18 mentions for STERIS and 14 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.18 beat STERIS's score of 0.98 indicating that Edwards Lifesciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Edwards Lifesciences 13 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDXX or STE?

In the previous week, STERIS had 15 more articles in the media than IDEXX Laboratories. MarketBeat recorded 18 mentions for STERIS and 3 mentions for IDEXX Laboratories. STERIS's average media sentiment score of 0.98 beat IDEXX Laboratories' score of 0.94 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STE or BDX?

In the previous week, Becton, Dickinson and Company had 9 more articles in the media than STERIS. MarketBeat recorded 27 mentions for Becton, Dickinson and Company and 18 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.21 beat STERIS's score of 0.98 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 19 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, RMD or STE?

ResMed has higher earnings, but lower revenue than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.44 $1.40B $10.37 18.62 STERIS $5.94B 3.38 $782.30M $7.93 25.95

Is RMD or STE more profitable?

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% STERIS 13.18% 14.15% 9.52%

Does the media favor RMD or STE?

In the previous week, STERIS had 1 more articles in the media than ResMed. MarketBeat recorded 18 mentions for STERIS and 17 mentions for ResMed. ResMed's average media sentiment score of 1.13 beat STERIS's score of 0.98 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 11 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

STERIS (STE) Competitors

$205.80 -1.77 (-0.85%)

Closing price 03:59 PM Eastern

Extended Trading

$206.00 +0.20 (+0.10%)

As of 05:03 PM Eastern

Compare

STE vs. BSX, EW, IDXX, BDX, and RMD

Should you buy STERIS stock or one of its competitors? MarketBeat compares STERIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with STERIS include Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), and ResMed (RMD). These companies are all part of the "health care equipment" industry.

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Boston Scientific had 40 more articles in the media than STERIS. MarketBeat recorded 58 mentions for Boston Scientific and 18 mentions for STERIS. Boston Scientific's average media sentiment score of 1.31 beat STERIS's score of 0.98 indicating that Boston Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	51 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
STERIS	11 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.46	$2.90B	$2.39	19.53
STERIS	$5.94B	3.38	$782.30M	$7.93	25.95

Boston Scientific has a net margin of 17.29% compared to STERIS's net margin of 13.18%. Boston Scientific's return on equity of 19.17% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
STERIS	13.18%	14.15%	9.52%

Boston Scientific has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Boston Scientific currently has a consensus price target of $85.08, suggesting a potential upside of 82.23%. STERIS has a consensus price target of $278.00, suggesting a potential upside of 35.09%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	1 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.80
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Boston Scientific beats STERIS on 12 of the 17 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.38	$782.30M	$7.93	25.95
Edwards Lifesciences	$6.07B	8.19	$1.07B	$1.88	45.89

STERIS presently has a consensus target price of $278.00, suggesting a potential upside of 35.09%. Edwards Lifesciences has a consensus target price of $95.96, suggesting a potential upside of 11.23%. Given STERIS's higher probable upside, equities analysts clearly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.81

Edwards Lifesciences has a net margin of 17.39% compared to STERIS's net margin of 13.18%. Edwards Lifesciences' return on equity of 15.19% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Edwards Lifesciences	17.39%	15.19%	11.71%

In the previous week, STERIS had 4 more articles in the media than Edwards Lifesciences. MarketBeat recorded 18 mentions for STERIS and 14 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.18 beat STERIS's score of 0.98 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	11 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	13 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats STERIS on 11 of the 17 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 13.18%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
STERIS	13.18%	14.15%	9.52%

IDEXX Laboratories currently has a consensus price target of $751.00, suggesting a potential upside of 31.75%. STERIS has a consensus price target of $278.00, suggesting a potential upside of 35.09%. Given STERIS's stronger consensus rating and higher probable upside, analysts clearly believe STERIS is more favorable than IDEXX Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, STERIS had 15 more articles in the media than IDEXX Laboratories. MarketBeat recorded 18 mentions for STERIS and 3 mentions for IDEXX Laboratories. STERIS's average media sentiment score of 0.98 beat IDEXX Laboratories' score of 0.94 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	11 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, STERIS has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

IDEXX Laboratories has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.45	$1.06B	$13.58	41.97
STERIS	$5.94B	3.38	$782.30M	$7.93	25.95

Summary

IDEXX Laboratories beats STERIS on 9 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.9%. STERIS pays out 31.8% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS has raised its dividend for 20 consecutive years and Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS currently has a consensus target price of $278.00, indicating a potential upside of 35.09%. Becton, Dickinson and Company has a consensus target price of $182.73, indicating a potential upside of 25.49%. Given STERIS's stronger consensus rating and higher possible upside, research analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

STERIS has a net margin of 13.18% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Becton, Dickinson and Company	5.33%	15.37%	7.11%

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.38	$782.30M	$7.93	25.95
Becton, Dickinson and Company	$21.84B	1.84	$1.68B	$3.95	36.86

In the previous week, Becton, Dickinson and Company had 9 more articles in the media than STERIS. MarketBeat recorded 27 mentions for Becton, Dickinson and Company and 18 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.21 beat STERIS's score of 0.98 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	11 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	19 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Summary

STERIS beats Becton, Dickinson and Company on 10 of the 19 factors compared between the two stocks.

How does STERIS compare to ResMed?

ResMed (NYSE:RMD) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

ResMed currently has a consensus price target of $279.82, indicating a potential upside of 44.95%. STERIS has a consensus price target of $278.00, indicating a potential upside of 35.09%. Given ResMed's higher probable upside, equities analysts plainly believe ResMed is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

ResMed has higher earnings, but lower revenue than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.44	$1.40B	$10.37	18.62
STERIS	$5.94B	3.38	$782.30M	$7.93	25.95

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
STERIS	13.18%	14.15%	9.52%

55.0% of ResMed shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. ResMed pays out 23.1% of its earnings in the form of a dividend. STERIS pays out 31.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and STERIS has increased its dividend for 20 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and lower payout ratio.

ResMed has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

In the previous week, STERIS had 1 more articles in the media than ResMed. MarketBeat recorded 18 mentions for STERIS and 17 mentions for ResMed. ResMed's average media sentiment score of 1.13 beat STERIS's score of 0.98 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	11 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats STERIS on 12 of the 20 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$20.23B	$7.18B	$6.74B	$23.32B
Dividend Yield	1.21%	1.21%	2.67%	4.05%
P/E Ratio	25.95	48.19	24.14	31.59
Price / Sales	3.38	74.54	511.88	20.84
Price / Cash	13.66	25.59	27.48	18.65
Price / Book	2.80	6.87	10.47	4.70
Net Income	$782.30M	$159.20M	$3.56B	$1.08B
7 Day Performance	-2.09%	-0.88%	0.87%	1.97%
1 Month Performance	-2.83%	5.18%	1.82%	3.32%
1 Year Performance	-14.66%	2.27%	25.66%	24.31%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.9126 of 5 stars	$205.80 -0.9%	$278.00 +35.1%	-14.0%	$20.23B	$5.94B	25.95	17,937
BSX Boston Scientific	4.9506 of 5 stars	$48.73 +0.4%	$85.92 +76.3%	-53.0%	$72.16B	$20.07B	20.39	59,000	Positive News Analyst Forecast Short Interest Increase
EW Edwards Lifesciences	3.5128 of 5 stars	$85.92 -0.1%	$95.96 +11.7%	+13.2%	$49.50B	$6.07B	45.70	16,000	Positive News
IDXX IDEXX Laboratories	3.4308 of 5 stars	$561.17 -0.2%	$751.00 +33.8%	+7.3%	$44.34B	$4.30B	41.32	11,000	Analyst Upgrade
BDX Becton, Dickinson and Company	4.9339 of 5 stars	$150.23 -0.6%	$183.64 +22.2%	-15.1%	$41.65B	$21.84B	38.03	72,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to ResMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Do institutionals and insiders believe in BSX or STE?

Does the media refer more to BSX or STE?

Which has preferable earnings and valuation, BSX or STE?

Is BSX or STE more profitable?

Which has more risk and volatility, BSX or STE?

Do analysts recommend BSX or STE?

Summary

How does STERIS compare to Edwards Lifesciences?

Which has stronger valuation and earnings, STE or EW?

Do analysts recommend STE or EW?

Is STE or EW more profitable?

Does the media refer more to STE or EW?

Which has more risk & volatility, STE or EW?

Do institutionals & insiders believe in STE or EW?

Summary

How does STERIS compare to IDEXX Laboratories?

Do insiders & institutionals believe in IDXX or STE?

Is IDXX or STE more profitable?

Do analysts rate IDXX or STE?

Does the media refer more to IDXX or STE?

Which has more volatility and risk, IDXX or STE?

Which has stronger earnings and valuation, IDXX or STE?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Is STE or BDX a better dividend stock?

Do analysts rate STE or BDX?

Is STE or BDX more profitable?

Do institutionals and insiders hold more shares of STE or BDX?

Which has stronger valuation & earnings, STE or BDX?

Does the media refer more to STE or BDX?

Which has more volatility & risk, STE or BDX?

Summary

How does STERIS compare to ResMed?

Do analysts prefer RMD or STE?

Which has stronger valuation and earnings, RMD or STE?

Is RMD or STE more profitable?

Do insiders and institutionals hold more shares of RMD or STE?

Is RMD or STE a better dividend stock?

Which has more volatility and risk, RMD or STE?

Does the media favor RMD or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools